BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlu-Aß antibody programme effective after antitrust clearance and closing: Stockholm, Sweden Saturday, Fe ...

Novo Nordisk A/S was the biggest leader among large stocks during the session, gaining 5.8%, and DNO ASA gained 5.4%. Carlsberg A/S Series A rounded out the top three leaders on Friday, with shares ...

Sweden’s BioArctic today revealed that the US Federal Trade Commission (FTC) has cleared the proposed deal with Bristol Myers ...

Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement ...

BioArctic AB's (publ) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as sales of Leqembi reached ?

Nordic stocks gained Monday, with the OMX Nordic 40 Index rising 1.1%. Saab AB Series B was the biggest leader among large stocks during the session, surging 16.2%, and BioArctic AB Series B rose 9.1% ...

BioArctic signed the first deal for its “brain transporter” with Bristol Myers Squibb late last year. The deal is worth up to $1.4bn and allows the US drugmaker to start trials using the technology to ...